Anebulo develops selonabant, an experimental drug for treating cannabis toxicity, mainly aimed at children and emergency departments. ANEB reports earnings on Wed, Nov 18, 2026.
Earnings
Earnings calendar →Seasonality
How ANEB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in ANEB in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANEB is in one of them and how their past ANEB trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ANEB in an article yet. Here's the latest on the wider market.
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals is a drug developer based in Lakeway, Texas, working on treatments for cannabis toxicity. Its lead candidate, selonabant, is designed to reverse the effects of cannabis intoxication and shorten recovery time. The company is focused on an intravenous version for children who have been accidentally poisoned by cannabis, with emergency departments as the intended users. Selonabant is still in clinical development and has not been approved for sale.
- Headquarters
- Lakeway, TX